There’s Rx Savings for Americans in Canada and Elsewhere If Needed!
Last week, we issued our first PharmacyChecker.com quarterly International Drug Price Savings Report, which showed that American consumers can potentially save, on average, 70% on 20 top-prescribed brand name drugs when buying from a Canadian pharmacy approved in our Verification Program. The report shows international pharmacy savings by country or group of countries: U.S., Canada, Australia/New Zealand/UK, India, and Turkey. We intend to issue this savings report every three months.
We chose the 20 medications based on IMS Health data on the most popularly prescribed non-controlled medications in 2015, and the prices were collected during February and March 2017. Ten of the medications are available in the U.S. as a generic, in which case American consumers will often – but not always – find the lowest prices locally.
Something unexpected happened at a dog and pony show staged at the National Press Club on April 4, where the Partnership for Safe Medicines (PSM) gave its campaign against prescription drug importation and international online pharmacies the imprimatur of technocratic expertise. Former FDA Commissioner Dr. Andrew Von Eschenbach, in opposing importation as unsafe, and “frightening” said that 29 countries have regulatory systems for drug safety comparable to the U.S. Was that a mistake? No. We need to get that list of 29 countries and create standards for distribution and refine guidance for consumers to help more Americans import lower cost medications from those countries.
I derived the number 29 because Dr. Eschenbach said: “of the 96 countries around the world that can supply drugs only 30% have a functional regulatory infrastructure that’s comparable to the one that we have at the Food and Drug Administration.” Simple math showed 30% of 96 is 28.8. I rounded to 29!
Granted, Dr. Eschenbach would say that I was taking his words out of context. (more…)
The executive director of Prescription Justice, Jodi Dart, published an op-ed in Morning Consult earlier this week called The Rx Rip-Off. The piece does contain Ms. Dart’s opinions but there are also some facts reported, ones based on a Zogby poll on drug prices commissioned by Prescription Justice. The poll shows that 90% of Americans are united on the need for the government to take action to make medication more affordable! As an incredible coincidence, President Trump tweeted just hours after the op-ed was published that “Pricing for the American people will come way down!”
There’s a lot in this poll that I look forward to writing about but let’s consider some of the broad findings of the poll:
75.5% of Americans agree with President Trump that the “drug companies are getting away with murder:
29.6% of Americans say they have not filled a prescription because of cost.
4.2% say they currently get prescription medication from a Canadian or other international online pharmacy.
77% of respondents who had an opinion on the issue of importation laws (522 out of 674) supported reforms so that consumers could lawfully purchase medicines from Canada or other countries.
Only 15% of respondents were actually against legalizing personal drug importation (23% of those who had an opinion).
Since Americans started importing medications for personal use in larger numbers at the beginning of the last decade, the Pharmaceutical Researchers and Manufacturers of America (PhRMA), Big Pharma, has engaged in media and government relations scare tactics to try and stop them. Apparently, when it comes to foreign versions of the new FDA-Approved Emflaza, which treats Duchenne Muscular Dystrophy, one board member of PhRMA supports importation!
Last week, I wrote about the decision of drug company Marathon Pharmaceuticals to postpone selling Emflaza over pricing concerns and how the issue shines a bright light on the benefits of personal drug importation. To summarize: some folks are outraged because Emflaza (deflazacort) was launched at a price of $89,000 for a one year supply. This seems insane when foreign versions of deflazacort, which cost 1% that amount (less than $1000), are already imported for personal use.
PhRMA is trying to distance itself from Marathon, just like it did with Martin Shkreli, former CEO of Turning Pharmaceuticals, when the price of Daraprim jumped from $13.50 to $750 a pill overnight. The CEO of Marathon, Jeff Aronin, however, sits on PhRMA’s Board of Directors! Last week, John Carroll of Endpoints News predicted last week that Aronin might be dropped. As of today, he’s still there.
Mr. Aronin wrote a letter to the Duchenne community that fully acknowledged American kids were already being treated with an unapproved foreign version of deflazacort. In his words: “As we all know, deflazacort was being used without FDA approval — and without ever having been approved anywhere in the world for Duchenne — by a very small group of patients (roughly 7 to 9 percent) in the Duchenne community who imported it from overseas.”
But does he support it? I mean, after all, the “score” for Marathon is that once it’s available for sale in the U.S., it will be purchased here. At least for the time being, this PhRMA board member does support it and seems to have no concern whatsoever whether the foreign version is safe and effective, not should he, since, like other medications, it was approved for safety and efficacy elsewhere. In noting that Marathon will “pause our commercialization” of Emflaza,” maintain its Expanded Access Patient Assistance Program, Aronin also state: “Patients currently receiving deflazacort from other sources may continue to have that option.” Damn right.
Is it hypocritical of PhRMA to diss Marathon? After all, brand drug companies jacked prices 130 times the inflation rate in 2015. Forty-five million Americans didn’t fill a prescription in 2016 due to cost. PhRMA will continue its practice of legal bribery and unleash a new, shiny PR campaign about life sciences and innovation — to prevent legislative and regulatory reforms that would lower drug prices. It’s going to take an unpredictable, unexpected populist wave of American anger at drug companies to bring their house down. In the meantime, maybe the people will take a hint from one PhRMA board member and import unapproved and lower cost medications.
Personal drug importation works! This week, drug company Marathon announced it is postponing the launch of Emflaza, its recently FDA-approved version of an off-patent drug called deflazacort, in the face of heavy scrutiny by Senator Bernie Sanders and Congressman Elijah Cummings over its price tag – $89,000 a year. This drug, which treats Duchenne Muscular Dystrophy (DMD), is available under the brand name Calcort in the United Kingdom at about 99% less (about $750) than the current U.S. “postponed” price. Generic versions of deflazacort are also available internationally among verified online pharmacies at an annual price tag of about $650.
For some background on the disease and treatment: DMD is a “genetic disorder characterized by progressive muscle degeneration and weakness.” It mostly afflicts boys, with onset ranging from ages 3-5. It’s caused by the absence of a protein called dystrophin. For more, see the Muscular Dystrophy Association’s (MDA) website. According to the MDA, corticosteroids, including deflazacort, help slow the disease’s progression.
For a critique of the Emflaza price read Sanders and Cummings’ letter. No one could do better than that. Marathon CEO Jeff Aronin attempts to rationalize the price here but it almost reads like an apology. They argue that no consumer will deal with the $89,000 price tag because health insurers only charge a $20 co-pay and they have patient assistance programs to help the uninsured. It’s never that perfect, at all: people always slip through the cracks and we’re not forcing people to go without needed medication or go into bankruptcy to get it. Right?
So now a fist full of truth about this medication and safe online access to affordable medicines to shine a bright light on the lifeline that is personal drug importation… (more…)
Joe and Terry Graedon have been helping Americans make better health decisions for the last 40 years, including through their syndicated radio show on National Public Radio called The People’s Pharmacy. As you can imagine, their listeners are interested in prescription drug safety and savings. Our CEO was on their show this past Saturday and I’d like to tell you about it, especially if you want to learn how to save money on brand name drugs.
The CEO of PharmacyChecker.com, Tod Cooperman, MD, is also the founder and president of ConsumerLab.com, the leading evaluator of health and wellness products. ConsuemrLab.com has worked with The People’s Pharmacy in the past to test prescription medications. While I believe that generics sold in the U.S. are usually of the highest quality, equal to or better than generics in most other countries, ConsumerLab.com’s findings show that some generic medications in the U.S. are not always equal to the brand. Due to his expertise is drug quality and his knowledge about drug prices, The People’s Pharmacy brought Dr. Cooperman on to their show last week to talk about Narrow Therapeutic Index (NTI) drugs. Listen to the show! (See minutes 6:50-18:00).
For NTI medications, it’s even more important that the active pharmaceutical ingredient is present in the exact amount required. When NTI medications have too much of the active pharmaceutical ingredient, it can be toxic; but those that have too little may not be adequately efficacious. Most NTI drugs are available in generic form, which usually means they are low cost, even without insurance, and usually lower-priced than in Canada and other countries, too! The opposite holds true for brands.
Some providers are deciding that it’s important for their patients stick with the brand for NTI drugs for the reasons stated above. But the prices here are often too high. In the radio show, Dr. Cooperman recommends looking internationally for those who can’t afford the brand locally. Americans can often find discounts averaging 80% internationally on Brand name NTI drugs. Last summer, when we read The Graedon’s Guide to Saving Money on Medicines, we noticed the list of NTI drugs and wanted to compare drug prices domestically and internationally. Our research from Fall 2016 is below.
Narrow Therapeutic Index (NTI) Drugs: Brand Name Price Comparison (U.S., Canada, International*)